EA202090587A1 - Способ получения сплит-вакцины с на гриппа - Google Patents
Способ получения сплит-вакцины с на гриппаInfo
- Publication number
- EA202090587A1 EA202090587A1 EA202090587A EA202090587A EA202090587A1 EA 202090587 A1 EA202090587 A1 EA 202090587A1 EA 202090587 A EA202090587 A EA 202090587A EA 202090587 A EA202090587 A EA 202090587A EA 202090587 A1 EA202090587 A1 EA 202090587A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- influenza
- split vaccine
- vaccine
- split
- stem region
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 238000010306 acid treatment Methods 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 229960003971 influenza vaccine Drugs 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Предложен способ получения сплит-вакцины на основе HA гриппа, которая продуцирует антитело, которое связывается со стволовой областью HA гриппа, причем стволовая область HA менее вероятно подвергается антигенной изменчивости. Сплит-вакцину на основе HA гриппа подвергают кислотной обработке. Посредством кислотной обработки получают сплит-вакцину с HA, которая продуцирует антитело, которое связывается с LAH стволовой области HA. Эта сплит-вакцина против гриппа обладает превосходной способностью против заражения другими вирусами гриппа различной антигенности.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017169230 | 2017-09-04 | ||
JP2018137952A JP7403733B2 (ja) | 2017-09-04 | 2018-07-23 | インフルエンザhaスプリットワクチンの製造方法 |
PCT/JP2018/032537 WO2019045090A1 (ja) | 2017-09-04 | 2018-09-03 | インフルエンザhaスプリットワクチンの製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202090587A1 true EA202090587A1 (ru) | 2020-08-24 |
Family
ID=65815411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090587A EA202090587A1 (ru) | 2017-09-04 | 2018-09-03 | Способ получения сплит-вакцины с на гриппа |
Country Status (10)
Country | Link |
---|---|
US (1) | US11732031B2 (ru) |
EP (1) | EP3679948A4 (ru) |
JP (1) | JP7403733B2 (ru) |
KR (1) | KR20200047629A (ru) |
CN (1) | CN111372605A (ru) |
AU (1) | AU2018325899B2 (ru) |
CA (1) | CA3074581A1 (ru) |
EA (1) | EA202090587A1 (ru) |
PH (1) | PH12020500414A1 (ru) |
SG (1) | SG11202001937TA (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7403733B2 (ja) | 2017-09-04 | 2023-12-25 | 国立感染症研究所長 | インフルエンザhaスプリットワクチンの製造方法 |
MX2021010685A (es) * | 2019-03-04 | 2021-12-10 | Sumitomo Pharma Co Ltd | Método para producir vacuna fraccionada de hemaglutinina (ha) contra la influenza. |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008054481A2 (en) | 2006-03-24 | 2008-05-08 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Improved inactivated influenza virus compositions |
JPWO2008114819A1 (ja) | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
WO2010010467A2 (en) | 2008-07-25 | 2010-01-28 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
WO2010047509A2 (ko) | 2008-10-24 | 2010-04-29 | 아주대학교 산학협력단 | 친화도와 안정성이 향상된 항 dr5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물 |
CN101524538A (zh) * | 2009-03-26 | 2009-09-09 | 成都康华生物制品有限公司 | 一种流感-大流行流感二价联合疫苗及其制备方法 |
WO2011111966A2 (en) | 2010-03-08 | 2011-09-15 | Celltrion, Inc. | Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses |
CN102939103A (zh) | 2010-03-30 | 2013-02-20 | 西奈山医学院 | 流感病毒疫苗及其应用 |
ES2728433T3 (es) | 2011-04-21 | 2019-10-24 | Ology Bioservices Inc | Procedimientos para aislar y cuantificar un antígeno de vacunas |
CN104302317B (zh) * | 2012-05-16 | 2016-07-06 | Kj生物科学有限公司 | 新型和改进的流感疫苗 |
KR20140118682A (ko) | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 a 바이러스 중화 결합 분자를 포함하는 조성물 |
JP2017525766A (ja) | 2014-08-18 | 2017-09-07 | サノフィ パスツール インコーポレイテッド | アルキル化インフルエンザワクチン |
EP3240567A2 (en) | 2014-12-31 | 2017-11-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Novel multivalent nanoparticle-based vaccines |
JP7403733B2 (ja) | 2017-09-04 | 2023-12-25 | 国立感染症研究所長 | インフルエンザhaスプリットワクチンの製造方法 |
KR20210034614A (ko) | 2018-07-23 | 2021-03-30 | 국립감염증연구소장이 대표하는 일본국 | 인플루엔자 백신을 포함하는 조성물 |
-
2018
- 2018-07-23 JP JP2018137952A patent/JP7403733B2/ja active Active
- 2018-09-03 EP EP18852584.4A patent/EP3679948A4/en active Pending
- 2018-09-03 SG SG11202001937TA patent/SG11202001937TA/en unknown
- 2018-09-03 EA EA202090587A patent/EA202090587A1/ru unknown
- 2018-09-03 CN CN201880070955.0A patent/CN111372605A/zh active Pending
- 2018-09-03 AU AU2018325899A patent/AU2018325899B2/en active Active
- 2018-09-03 CA CA3074581A patent/CA3074581A1/en active Pending
- 2018-09-03 KR KR1020207009033A patent/KR20200047629A/ko not_active Application Discontinuation
-
2019
- 2019-03-04 US US16/292,065 patent/US11732031B2/en active Active
-
2020
- 2020-03-02 PH PH12020500414A patent/PH12020500414A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3679948A4 (en) | 2021-04-28 |
AU2018325899A1 (en) | 2020-04-09 |
CN111372605A (zh) | 2020-07-03 |
EP3679948A1 (en) | 2020-07-15 |
KR20200047629A (ko) | 2020-05-07 |
US11732031B2 (en) | 2023-08-22 |
CA3074581A1 (en) | 2019-03-07 |
JP7403733B2 (ja) | 2023-12-25 |
JP2019043937A (ja) | 2019-03-22 |
US20190345231A1 (en) | 2019-11-14 |
PH12020500414A1 (en) | 2021-03-08 |
AU2018325899B2 (en) | 2023-04-20 |
SG11202001937TA (en) | 2020-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018004321A2 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
CL2017001610A1 (es) | Anticuerpos humanos para hemagglutinina de influenza | |
EA201891339A1 (ru) | Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб | |
BR112016022113A2 (pt) | anticorpos anti-hemaglutinina do vírus influenza b e métodos de uso | |
UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
BR112017009817A2 (pt) | anticorpos anti-il-1beta e métodos de utilização | |
EA201691648A1 (ru) | Способ получения противогрибковых соединений | |
EA201691649A1 (ru) | Способ получения противогрибковых соединений | |
EA201791907A1 (ru) | Бивалентная вакцина против вируса свиного гриппа | |
BR112017015880A2 (pt) | anticorpos, usos e métodos | |
UY36394A (es) | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso. | |
MX2017016896A (es) | Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos. | |
EA201990010A1 (ru) | Вакцина против вируса инфекционного бронхита | |
EA201790558A1 (ru) | Композиция с пониженной иммуногенностью | |
BR112018077210A8 (pt) | Vírus de enterite de pato e usos do mesmo | |
EA201690857A1 (ru) | Конъюгатные вакцины на основе сальмонеллы | |
UA116697C2 (uk) | Композиція для запобігання зараженню видами роду mycoplasma | |
EA202090587A1 (ru) | Способ получения сплит-вакцины с на гриппа | |
BR112015032388A2 (pt) | métodos e composições para as vacinas contra o vírus da dengue | |
MX363464B (es) | Vacunas contra influenza h5. | |
MX2018014955A (es) | Vacunas atenuadas vivas del virus de la influenza equina. | |
JP2019043937A5 (ru) | ||
WO2017053525A3 (en) | Influenza vaccine and therapy | |
EA201990768A1 (ru) | Оптимизированные синтетические консенсусные иммуногенные композиции, нацеленные на белок активации фибробластов | |
PE20190225A1 (es) | Un metodo para reducir la contaminacion de huevo |